This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Subcortical vascular dementia피질하 혈관성 치매

Contents and key points
ItemDetails
A. Classification codesICD-10: F01.2 | Special Copayment Reduction: V810 (severe intractable disease, 5 years)
B. SynonymsBinswanger disease, subcortical arteriosclerotic encephalopathy, lacunar state (état lacunaire), CADASIL
C. Adult onsetPossible — mainly 60s–80s; CADASIL in 30s–50s; continuous, gradual onset is characteristic.
1. HistoryDescribed by Binswanger in 1894; additional records by Alzheimer in 1902; clinical recognition expanded with the spread of CT/MRI in 1987; CADASIL gene discovered in 1993.
2. CausesSmall vessel disease from hypertension (lipohyalinosis); recurrent lacunar infarcts; CADASIL (NOTCH3 variants); diabetic small vessel disease.
3. GeneticsCADASIL: NOTCH3 (chromosome 19) autosomal dominant; CARASIL: HTRA1 autosomal recessive; sporadic: APOE ε4, vascular risk genes.
4. General epidemiologyMost common subtype of vascular dementia; CADASIL: about 4–5 per 100,000 population; more common in patients with hypertension and diabetes.
5. PathophysiologySmall vessel lipohyalinosis → white matter ischemia → disconnection of subcortical neural connections → frontal-subcortical circuit dysfunction → reduced executive function and processing speed.
6. SymptomsReduced executive function; reduced processing speed; gait disturbance (short-step gait, freezing); urinary incontinence; memory impairment relatively mild; depression and apathy.
7. SignsMRI: extensive white matter hyperintensities (Fazekas grade 2–3), multiple lacunar infarcts; gait apraxia; pyramidal signs.
8. ScreeningAssess white matter degeneration on brain MRI in patients with hypertension and diabetes; NOTCH3 gene testing when there is a family history.
9. DiagnosisClinical symptoms + MRI small vessel disease (extensive white matter degeneration, multiple lacunes); VasCog 2014 criteria; CADASIL genetic testing.
10. TreatmentStrict blood pressure control; diabetes management; antiplatelet therapy (to prevent recurrence of lacunar infarcts); gait and fall rehabilitation; symptom management.
11. PrognosisGradual progression; gait disturbance and fall risk; aggressive blood pressure control affects the rate of progression; CADASIL leads to severe disability in the 50s–60s.
12. PreventionEarly, strict blood pressure control is key; complete smoking cessation in CADASIL; diabetes management; aerobic exercise.
13. ReferencesWardlaw JM et al. Lancet Neurol 2019 and 9 other references

1. History

Subcortical vascular dementia originates from 'subcortical arteriosclerotic encephalopathy' reported in 1894 by the German neuropathologist Otto Binswanger. Binswanger described patients in whom progressive dementia developed with severe atrophy and rarefaction of the deep white matter beneath the cerebral cortex. In 1902, Alois Alzheimer pathologically confirmed fibrinoid necrosis of small vessels in cases of the same type.

However, Binswanger disease was regarded as a very rare disease for most of the 20th century. In 1987, Hack et al. reported an association between white matter low-density lesions on CT and clinical dementia, and with the subsequent spread of MRI, it became known that white matter hyperintensities (WMH) on T2/FLAIR are observed very commonly, greatly expanding clinical recognition of subcortical vascular dementia.

In 1993, Tournier-Lasserve et al. identified mutation of the NOTCH3 gene on chromosome 19 as the cause of CADASIL, a hereditary disease causing recurrent subcortical infarcts and white matter degeneration. CADASIL is the best-characterized cause of hereditary subcortical vascular dementia and is understood as a genetic model of Binswanger disease.

In ICD-10 in 2002, F01.2 was established as a code encompassing dementia due to subcortical small vessel disease such as Binswanger disease and CADASIL, and in the VasCog 2014 criteria subcortical vascular dementia was recognized as a major subtype of vascular cognitive impairment.


2. Causes

The cause of subcortical vascular dementia is cerebral small vessel disease (CSVD). CSVD causes ischemic damage to the subcortical white matter, basal ganglia, thalamus, and brainstem through lesions of perforating arteries and small arteries.

Hypertensive small vessel disease

Chronic hypertension induces lipohyalinosis, vessel wall thickening, and luminal narrowing in the walls of small vessels, causing recurrent lacunar infarcts and chronic ischemic changes (WMH) in the deep white matter and subcortical structures. This is the most common cause of subcortical vascular dementia.

Cerebral amyloid angiopathy (CAA)

CAA, commonly accompanying Alzheimer disease and old age, involves amyloid deposition in the walls of cortical and leptomeningeal vessels, which increases vascular fragility and can cause recurrent lobar hemorrhage and subcortical ischemic changes.

CADASIL (hereditary)

CADASIL due to NOTCH3 gene variants typically causes migraine (40%), recurrent ischemic stroke (30s–60s), psychiatric symptoms (depression, mania), and progressive cognitive decline. On MRI, characteristic lesions of the frontal lobe and temporal pole white matter (anterior temporal pole lesion) are the imaging marker of CADASIL.

Diabetic small vessel disease

Diabetes affects cerebral small vessels independently of hypertension and increases the risk of WMH and subcortical infarcts.


3. Genetics

CADASIL is an autosomal dominant disease caused by mutation of the NOTCH3 gene on chromosome 19. NOTCH3 is a receptor on vascular smooth muscle cells, and pathogenic mutations (mainly cysteine residue variants within EGF-like repeat domains) cause abnormal accumulation of the NOTCH3 extracellular domain and vascular damage. More than 300 pathogenic variants have been identified to date. Penetrance is high, but there is variation in expressivity within families.

CARASIL (cerebroretinal microangiopathy with calcifications and cysts) is due to autosomal recessive mutation of the HTRA1 gene and is characterized by early-onset subcortical ischemic changes, non-traumatic alopecia, and spinal abnormalities (spondylosis). It is mainly reported in East Asian (Japanese, Korean) populations.

In sporadic subcortical vascular dementia, polymorphisms of APOE ε4, MTHFR C677T, and blood pressure regulation-related genes (ACE, AGT) increase risk. Recent GWAS have found loci associated with white matter lesions, such as COL4A1/COL4A2 and FOXF2.


4. General epidemiology

Subcortical vascular dementia is the most common subtype of vascular dementia, and especially in Asia, dementia due to subcortical small vessel disease accounts for a high proportion of all vascular dementia. In MRI studies of the population aged 65 and over, WMH are present to some degree in about 60–80%, but severe WMH (Fazekas grade 3) are present in about 5–10%, in which case the risk of cognitive impairment increases significantly.

The prevalence of CADASIL is estimated at about 4–5 per 100,000 population, but because of underdiagnosis the actual figure is presumed to be higher. Age at onset is the 30s–50s, dementia occurs in the 50s–60s, and severe disability is reached in the 60s–70s. Many CADASIL families have also been reported in Korea.


5. Pathophysiology

The core mechanism of subcortical vascular dementia is white matter damage due to small vessel disease and disconnection of frontal-subcortical circuits. Projection fibers, association fibers, and commissural fibers connecting the cerebral cortex, such as the frontal and parietal lobes, with the basal ganglia, thalamus, and cerebellum pass through the white matter. White matter damage from small vessel disease disconnects these connections and impairs the function of the frontal-subcortical circuits.

The frontal-subcortical circuits are involved in executive function, processing speed, working memory, motivation, and emotion regulation. Therefore, in subcortical vascular dementia, reduced executive function, reduced processing speed, apathy, and depression are more prominent than memory impairment. Circuits responsible for gait are also damaged, so gait disturbance appears early.


6. Symptoms

In subcortical vascular dementia, the cognitive symptoms are dominated by reduced executive function (planning, strategy, flexibility) and reduced processing speed rather than episodic memory. Patients have difficulty planning and organizing complex tasks, and attention shifting and task switching become slow. Memory impairment is mainly a retrieval deficit type that improves with cues; even when free recall is difficult, cued recall is relatively preserved.

Gait disturbance is characteristic. Parkinsonian-like gait appears, with short-step gait (marche à petit pas), unsteady gait, freezing gait, and loss of postural reflexes. Urinary incontinence results from damage to the frontal subcortical bladder control circuit. Depression, apathy, and emotional incontinence are common, and are explained by damage to frontal-subcortical connections. Migraine (especially migraine with aura) is an important early symptom of CADASIL.


7. Signs

On brain MRI, extensive white matter hyperintensities (WMH, FLAIR T2) and multiple lacunar infarcts are characteristic. WMH of Fazekas grade 2 or higher suggest clinically meaningful small vessel disease. In CADASIL, white matter lesions of the anterior temporal pole are very characteristic, and this site is rarely involved in hypertensive WMH. Multiple microbleeds may be observed on SWI (susceptibility-weighted imaging).

On neurological examination, mild pyramidal signs (hyperreflexia, Babinski sign), gait apraxia, asterixis, and dysarthria may be present.


8. Screening

When cognitive decline, gait disturbance, and urinary incontinence occur in patients with hypertension and diabetes, brain MRI is performed to evaluate WMH and lacunar infarcts. When CADASIL is suspected (migraine with middle-age onset, recurrent lacunar infarcts, family history), NOTCH3 gene testing is performed. Confirming NOTCH3 deposition on skin biopsy is also used for diagnosis. On neuropsychological testing, the Trail Making Test B, digit span, and processing speed tests reflect subcortical executive dysfunction well.


9. Diagnosis

Diagnosis of subcortical vascular dementia consists of ① meeting dementia criteria with mainly executive function, processing speed, and gait disturbance, ② extensive WMH (Fazekas grade 2–3) and/or multiple lacunar infarcts on MRI, and ③ exclusion of other causes (Alzheimer disease, Parkinson disease, NPH, etc.). Amyloid PET or plasma p-tau217 is useful for differentiation from Alzheimer dementia. Normal pressure hydrocephalus (NPH) resembles subcortical vascular dementia with its triad of gait disturbance, urinary incontinence, and cognitive impairment, and is differentiated by brain MRI (ventricular enlargement, Evans index >0.3, disproportionately enlarged subarachnoid space hydrocephalus) and the CSF tap test (gait improvement after draining 30 mL of CSF).


10. Treatment

Blood pressure control is the most important part of treatment of subcortical vascular dementia. Target blood pressure <130/80 mmHg. In the SPRINT-MIND study, intensive blood pressure control (SBP <120 mmHg) significantly reduced the incidence of mild cognitive impairment. Diabetes control (HbA1c <7%), smoking cessation, and statin treatment are combined. Antiplatelet agents (aspirin or clopidogrel) are used to prevent recurrence of lacunar infarcts. In CADASIL, clopidogrel is preferred over aspirin, and anticoagulants are avoided because they may actually increase bleeding risk in CADASIL. Gait rehabilitation, fall prevention programs, bladder training (urinary incontinence), and cognitive rehabilitation are important non-pharmacological treatments. Evidence for cholinesterase inhibitors in subcortical vascular dementia is limited, but improvement of executive function has been reported in some clinical trials.


11. Prognosis

Subcortical vascular dementia progresses gradually, and when blood pressure is well controlled the rate of progression may be somewhat slowed. Falls, fractures, and immobility due to gait disturbance are the main complications. Urinary incontinence and mobility impairment are major reasons for institutionalization. CADASIL patients develop severe disability in their 50s–60s, and the whole course progresses over about 20–30 years.


12. Prevention

Early detection and strict control of blood pressure is the most important single strategy for preventing subcortical vascular dementia. Because blood pressure in midlife (40s–50s) is strongly associated with white matter lesions and cognitive decline in old age, it is important to begin blood pressure management from midlife. In CADASIL, smoking, which greatly increases stroke risk, must be completely prohibited, and ergotamine and triptans are avoided in migraine treatment because of ischemic risk. Early detection and management of diabetes, moderation of alcohol intake, and aerobic exercise contribute to preventing small vessel disease.


13. References

  1. Wardlaw JM, Smith C, Dichgans M. Small vessel disease: mechanisms and clinical implications. Lancet Neurol. 2019;18(7):684-696. DOI: 10.1016/S1474-4422(19)30079-1. PMID: 31097385.
  2. Chabriat H, Joutel A, Dichgans M, et al. Cadasil. Lancet Neurol. 2009;8(7):643-653. DOI: 10.1016/S1474-4422(09)70127-9. PMID: 19539236.
  3. Dichgans M, Leys D. Vascular Cognitive Impairment. Circ Res. 2017;120(3):573-591. PMID: 28154105.
  4. Iadecola C, Duering M, Hachinski V, et al. Vascular Cognitive Impairment and Dementia. J Am Coll Cardiol. 2019;73(25):3326-3344. PMID: 31226035.
  5. SPRINT MIND Investigators for the SPRINT Research Group. Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia. JAMA. 2019;321(6):553-561. DOI: 10.1001/jama.2018.21442. PMID: 30688979.
  6. Sachdev P, Kalaria R, O'Brien J, et al. Diagnostic criteria for vascular cognitive disorders: a VASCOG statement. Alzheimer Dis Assoc Disord. 2014;28(3):206-218. PMID: 24632990.
  7. Pantoni L. Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol. 2010;9(7):689-701. DOI: 10.1016/S1474-4422(10)70104-6. PMID: 20610345.
  8. Gorelick PB, Scuteri A, Black SE, et al. Vascular contributions to cognitive impairment and dementia. Stroke. 2011;42(9):2672-2713. PMID: 21778438.
  9. van der Flier WM, Skoog I, Schneider JA, et al. Vascular cognitive impairment. Nat Rev Dis Primers. 2018;4:18003. PMID: 29446769.
  10. Livingston G, Huntley J, Liu KY, et al. Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. Lancet. 2024;404(10452):572-628. PMID: 39096926.